Vaxcyte(PCVX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Program Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- PCV Franchise Infant Indication: -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of ...